1 completed, 1 terminated. 2 Phase 1.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 2 | Completed 1, Terminated 1 |
Follow Repligen Corporation: new trials by email
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Safety of RG2077 in Patients With Multiple Sclerosis RG2077 (CTLA4-IgG4m) - Multiple Sclerosis, Multiple Sclerosis, Relapsing-Remitting | Phase 1 | Completed | National Institute of Allergy and Infectious Diseases (NIAID) | 20 | 2003-01-01 | 2017-03-27 |
| RG2133 (2',3',5'-Tri-O-Acetyluridine) in Mitochondrial Disease RG2133 (2',3',5'-tri-O-acetyluridine) - Mitochondrial Diseases | Phase 1 | Terminated | Repligen Corporation | 12 | 2005-08-05 |
Ataxia (1) · Autoimmune Diseases (1) · Mitochondrial Diseases (1) · Multiple Sclerosis (1) · Multiple Sclerosis, Relapsing-Remitting (1)
United States (1)